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Abstract
In forensic investigations, body fluids can provide crucial information and is helpful for
corroborating the circumstance of the case. For cases of sexual assaults or homicides, being able
to differentiate if the blood is peripheral blood or menstrual blood is important. Peripheral blood
can be indicative of a traumatic event, while menstrual blood is of a natural cause. Currently,
serology based methods are used for body fluid identification, however, their lack of sensitivity
and specificity remains an issue. MicroRNAs (miRNAs) are a class of non-protein coding nucleic
acids that are able to be co-extracted with DNA, and their small size (18-25 nucleotides) makes
them ideal for analyzing highly degraded forensic samples. This study used RT-qPCR to evaluate
the relative expression of candidate miRNAs miR-141 and miR-412, for their ability to distinguish
between menstrual and peripheral blood and to further enhance a previously validated miRNA
panel consisting of miR-200b, miR-891a, miR-10b, and miR-320. A population size of 50 samples
of peripheral blood, menstrual blood, feces, semen, urine, saliva, and vaginal fluid were tested. A
quadratic discriminant analysis matrix was used to facilitate the classification of unknown body
fluids using miRNA expression data. Our results established that using miR-141 and miR-412 in
conjunction with the previously validated panel allow for a prediction accuracy of 91.36%, an
increase of 3.36% over prediction accuracy without miRs 141 and 412. Overall, the relative
expression of miRNAs in body fluids is promising as a method of body fluid identification with
potential to be developed into a multiplex that could be easily integrated into forensic crime
laboratories.
Keywords: forensic science, forensic serology, body fluid identification, microRNA, menstrual
blood, reverse transcription-quantitative polymerase chain reaction
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Introduction
In forensic science, being able to identify the origin of a body fluid is important for piecing
together crime scenes. One of the most common body fluids encountered in forensic evidence is
blood. In cases of sexual assaults or homicides, knowing if the blood is peripheral blood or
menstrual blood is helpful for corroborating the circumstance of the case. Peripheral blood can be
indicative of a traumatic event, while menstrual blood is of a natural cause (1). Current methods
for blood identification are catalytic (luminol or phenolphthalein-tetramethybenzidine test),
microscopic (Takayama crystal test), or immunological tests (Rapid Stain Identification-Blood).
However, these tests do not have the ability to differentiate between peripheral blood and
menstrual blood.
Historically, methods for differentiating between peripheral blood and menstrual blood
were microscopic methods which were based on the identification of either endometrial or vaginal
epithelial cells in the menstrual blood (2). However, microscopic examinations have a low
discriminatory power and have been proven inadmissible in cases of sexual assault because
epithelial cells from the buccal cavity and male urethra cannot be distinguished from vaginal
epithelial cells using basic microscopy techniques (3). Recently, Verma et al. (4) used microscopic
analysis and the Teichmann test to distinguish between peripheral blood and menstrual blood using
a combination of hemoglobin content, red blood cells and white blood cell count. The Teichmann
test is a confirmatory blood test based on the formation of haematin crystals observed under a
microscope (5). It was found that menstrual blood would test negative using the Teichmann test
because menstrual secretions interfered with crystal formation. Menstrual blood was also found to
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have less red blood cells and white blood cells and more debris compared to peripheral blood when
viewed under a microscope (4).
Another method for differentiating peripheral blood from menstrual blood that is gaining
traction in forensics is an immunochromatographic method which uses the D-dimer assay to
identify menstrual blood. D-dimers are produced during fibrinolysis, the process of breaking down
fibrin in blood clots. Fibrinolysis prevents blood coagulation in order for menstrual blood to easily
exit the body. The mean plasma concentration of D-dimers in peripheral blood is 0.047 µg/mL
compared to 102 µg/mL in menstrual blood indicating that D-dimers are present in menstrual blood
at levels that are 200 times that of peripheral blood. (6-8). While Barker et.al and Holtkotter et. al
did have success with identifying menstrual blood using an immunochromatographic D-dimer test,
the D-dimer test could only be used as a presumptive test for menstrual blood due to the high false
positive rates found when post-mortem blood was tested. False positives were also seen when
blood from coronary artery disease patients and patients with a variety of other health conditions
was tested; as these conditions cause a related increase in the levels of D-dimers found in peripheral
blood.
Current Methods for Body Fluid Identification
Currently used forensic methods for body fluid identification only allow for single sample
analysis and can be time consuming and labor intensive. The majority of the body fluid
identification methods for blood are catalytic in nature. They rely on the peroxidase-like activity
of hemoglobin, and are not considered confirmatory due to the presence of known false positives
with oxidants and plant peroxidases (9). In recent years, using molecular methods for body fluid
identification has been of interest as a way to overcome the problems associated with chemical,
catalytic, microscopic and immunochromatographic tests.
5

The use of messenger RNA (mRNA) for body fluid identification is a molecular method
that has been widely studied for forensic science applications. mRNAs have gained interest in the
forensic science community because the relative abundance of mRNAs in cells (mRNA profile)
results in tissue-specific expression patterns that are unique to certain body fluids (10). A limitation
to using mRNA markers is their potential for degradation. Although mRNA markers can be
detected in body fluids for long periods of time in ideal storage conditions, when faced with
environmental factors that forensic science samples often encounter such as heat, light, and
moisture, the degradation rate is high (11).
The molecular method used in this study targets microRNAs (miRNAs). miRNAs are
small noncoding RNA molecules that are 18-25 nucleotides in length (12-13). miRNAs regulate
gene expression by inactivating mRNA which are necessary for translating the genetic information
into proteins through a process called gene silencing. Gene silencing occurs when miRNAs bind
with Argonaute (AGO) family proteins to produce a RNA Induced Silencing Complex (RISC).
The RISC binds to the 3’untranslated region (3’UTR) of the target mRNA and inactivates it by
either cutting the mRNA or inhibiting of translation which prevents the mRNA from being
translated to a protein, thus silencing the gene (16). miRNAs can be tissue specific and their
differential tissue expression can be used to identify body fluid origin with a high degree of
sensitivity and specificity (14-17). The small size of miRNAs allows them to withstand
environmental and chemical factors that cause degradation, making them ideal for forensic use
(18).
While miRNAs have been the subject of body fluid identification in forensic science
research, the use of miRNAs has not yet been implemented into forensic science casework. The
primary reason is that developmental validation of commercial kits is still underway. Another
6

reason it has yet to be implemented is because until recently, miRNA analysis still required a
separate extraction thus consuming valuable sample and increasing analysis time.
The use of miRNAs for body fluid identification described by Williams et al. in 2016 (19)
used high throughput sequencing to catalogue the entire transcriptome of small RNAs of feces,
semen, saliva, urine, peripheral blood, menstrual blood, perspiration, and vaginal secretions. A
panel of 8 miRNAs were identified as being differentially expressed in each of the eight
forensically relevant bodily fluids. The markers identified were miR-200b for peripheral blood,
miR-1246 for menstrual blood, miR320c for feces, miR10b-5p for urine/feces, miR 26b for saliva,
and miR-891a for semen. Two miRNAs identified on the panel for normalization and control
purposes were let-7g and let-7i. Additional research to determine if miRNAs could be
implemented in forensic casework was conducted by Layne et al. in 2019. (20) The study evaluated
the stability of the same miRNA panel in RNA extracts after exposure to compromising conditions
such as UV light, detergent, heat, and bleach treatments. Overall, the miRNAs studied were stable
and detectable after the majority of the treatments.
It has been determined that miRNAs are detectable in DNA extracts which alleviates the
problems of consuming more sample and increasing analysis time thus, allowing easier
implementation of miRNA analysis into forensic casework workflows (21-22). Previous studies
were conducted with RNA extracts obtained from a separate extraction, so a further study was
conducted in order to determine if miRNAs could be detected using DNA extraction methods
commonly used in the forensic laboratory (23-24). In 2019 Lewis et al. (25) conducted analysis on
a larger population size of semen, blood, saliva, and a limited number of menstrual secretions using
organic, silica column, and other DNA extraction methods. The study concluded that separate
RNA extraction was not necessary to detect miRNAs for analysis, though abundance of miRNAs
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is reduced and possibly expression patterns are changed in DNA extracts. The study also
performed a preliminary analysis of blood, semen, saliva, and menstrual secretions DNA extracts,
and the found that the body fluid DNA extracts could be used to correctly identify body fluids
using the 2016 miRNA RNA extracts panel, with the exception of menstrual secretions.
The purpose of this project was to identify a marker for menstrual blood, from candidates
described in the literature. Previously in the Seashols-Williams laboratory, a reduced miRNA
panel consisting of miR-200b, miR-320c, and miR-10b, and miR-891a were tested in duplicate in
DNA extracts using 50 samples each of menstrual blood, blood, semen, saliva, urine, feces, and
vaginal fluid with an 88% classification obtained (Table 1). However, menstrual blood had the
lowest classification accuracy of 62%, often misclassifying as vaginal fluid. Thus, in this work,
the goal was to identify, evaluate, and then incorporate potential menstrual blood markers into the
existing panel. Candidate markers were evaluated for their differential expression using the
previously described model used by Seashols-Williams and Lewis et al. (25).
Potential miRNA targets for menstrual blood
miR141-3p was first evaluated as a marker for distinguishing between menstrual blood and
peripheral in 2017 by Li et al. (12) Li used Exiqon’s miRUCRY TM LNA to screen potential
candidate markers and then, confirmed the markers ability to differentiate between peripheral
blood and menstrual blood using two quantitative methods, Taqman hydrolysis probes (TaqMan)
and SYBR Green fluorochrome (SYBR). For statistical analysis, they normalized to the reference
gene U6 snRNA and quantified using the Cq method. The results indicated that menstrual blood
could be differentiated from peripheral blood using both quantitative methods. In 2017, Li et al.
(26) also conducted a study to confirm the reliability of the marker miR141-3p through the
menstrual cycle days 1-5. The study concluded that miR141-3p was a reliable marker regardless
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of the time during the menstrual cycle the sample is collected. Another study conducted by Mayes
et al. (27) in 2017 used capillary electrophoresis for identifying forensically relevant body fluids
using miRNA analysis. While this method varies from using RT-qPCR, it used let-7g as the
endogenous reference gene and was able to differentiate menstrual blood from peripheral blood
using the marker miR-141-3p. Unfortunately in this study, a mixture of venous blood and semen
would not distinguishable from a mixture of menstrual blood and semen due to cross reactivity of
the markers miR-141-3p and miR-412-3p.
Another marker of interest evaluated in the literature is miR-412. miR-412 was first
introduced as a possible marker for menstrual blood in 2009 by Hanson et al. (17). In the study,
Hanson used the miScript Reverse Transcription Kit and RT-qPCR with the SYBR Green assay
for analysis. For statistical analysis, they normalized to the reference gene RNU6b and quantified
using the Ct method. miR-412 was used in conjunction with the miR-451 for the identification
of menstrual blood. The study concluded that miR-412 and miR-451 were strong candidates for
identifying menstrual blood, resulting in a clear separation between venous blood, vaginal
secretions, and menstrual blood. The study also conducted analysis with a mixture of venous blood
and vaginal secretions mixtures and demonstrated that a false positive for menstrual blood would
not be identified using the miR-412 and miR-451 markers. The results supported specificity of the
developed assay for menstrual blood. In 2015, Bexon and Williams (28) analyzed miR-412 as a
marker for menstrual blood throughout the full menstrual cycle. The analysis method used was
reverse transcription with the Taqman assay, the markers miR-93, miR-1260b, miR-203a, miR508, and SNORD-47 were used as endogenous controls, and data analysis was quantified using
the Cq method. The study concluded that miR-412 was highly specific for menstrual blood across
all volunteers regardless of lifestyle differences such as smoking, diet, hormonal changes, and
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pregnancy history. In 2018 O’Leary and Glynn (29) analyzed miR412 as a potential marker for
menstrual blood identification. The analysis method used was reverse transcription with the
Taqman assay, miR-16 was used an endogenous control, and data analysis was quantified using
the Cq method. This study also concluded that miR-412 was stably expressed in the menstrual
blood samples. These results highlighted the potential of miR-412 as a biomarker for menstrual
blood.
Materials and Methods
Sample Collection (Previously conducted work)
Body fluids used in this study were collected from individuals of varying age, ethnicity,
and gender in accordance with the VCU-IRB approved human subjects research protocol (VCU
HM20002931_CR5) and randomly selected for this project. For blood collection, the donor’s
finger was sterilized with an alcohol wipe and pricked using a finger lancet, and the blood was
deposited on a sterile cotton swab. Menstrual blood and vaginal secretion donors were instructed
to insert a sterile cotton swab two to three inches into the vagina and twist the swab while in the
vagina. Urine donors deposited their samples into a sterile collection cup. Feces donors were
instructed to collect feces as they were defecating onto a sterile cotton swab. Semen donors
deposited their samples into a sterile collection cup, which was aliquoted into microcentrifuge
tubes and stored at -80°C. Prior to extraction, semen aliquots were thawed on ice and 50 µl were
deposited onto sterile cotton swabs and dried. All swabs were stored at room temperature in swab
boxes and placed in biohazard bags after collection.
DNA Extraction
DNA extraction was conducted on 50 samples of vaginal fluid, feces, saliva, blood,
menstrual blood, and semen using the Qiagen QIAamp DNA Investigator Kit (Qiagen, Hilden,
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Germany) on the QiaCube (Qiagen) following the previously validated manufacturer protocol for
forensic casework samples. The final elution volumes were as follows: vaginal fluid 30 µL, feces
50 µL, saliva 30 µL, blood 30 µL, menstrual blood 30 µL, and semen 30 µL. Fifty samples of
urine were extracted manually using the Qiagen QIAamp DNA Micro Kit (Qiagen, Hilden,
Germany) following the previously validated manufacturer protocol. The final elution volume was
20 µL.
Reverse Transcription Quantitative PCR
Relative quantification of miRNAs present in the DNA extracts were obtained via RTqPCR. The miRNA candidates for menstrual blood miR-141-3p and miR-412, and reference
miRNAs let-7g and let-7i were quantified in 20 samples each of blood, saliva, vaginal fluid, semen,
and feces, urine, and menstrual blood from different donors. miR-141 and miR-412 were validated
prior to the experiment using menstrual blood. The samples tested were DNA extract, DNase
treated DNA extract, reverse transcribed miRNA from DNA extract, and reverse transcribed
miRNA from DNase treated DNA extract to ensure specificity of the primer to miRNA. Only
primers that showed amplification of product in the reverse transcribed DNA extract sample and
similar levels of product in the reverse transcribed DNase treated extract without amplification in
either of the two non-reverse transcribed DNA extract samples were used.
Reverse transcription quantitative PCR was performed using the qScript microRNA cDNA
Synthesis Kit (QuantaBiosciences Inc., Gaithersburg, MD). The polyadenylation was conducted
with 2 L of Poly(A) Tailing Buffer (5X) (QuantaBiosciences Inc.), 0.6 L of Poly (A) Polymerase
(QuantaBiosciences Inc.), and 7 L of DNA extract using the ProFlex PCR System (Thermo Fisher
Inc.) for the following incubation parameters: 37°C for 40 minutes, then 70°C for five minutes.
Reverse transcription was conducted with 10 µL of the Poly(A) Tailing Reaction, 9 µL of
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microRNA cDNA Reaction Mix (Quanta Biosciences Inc.), and 1 µL of qScript™ Reverse
Transcriptase (Quanta Biosciences Inc.) using the ProFlex PCR System (Thermo Fisher Inc.) for
the following incubation parameters: 42°C for 20 minutes, then 85°C for five minutes. For each
RT reaction, a reagent blank containing 7 µL of nuclease free water was included. Resultant cDNA
was stored at -20°C.
qPCR was conducted for each cDNA sample using a modified quarter-reaction protocol
containing 6.25 µL of PerfeCTa SYBR Green SuperMix (2X) (Quanta Biosciences Inc.), 0.25 µL
of 10 µM Integrated Device Technologies (San Jose, CA) microRNA Assay Primer, 0.25 µL of
PerfeCTa Universal PCR Primer (Quanta Biosciences Inc.), 2 µL of cDNA reaction, and 3.75 µL
of nuclease-free water. Thermal cycling was performed on the Applied Biosystems™
QuantStudio™ 6 Flex Real-Time PCR System (Life Technologies, Carlsbad, CA) using the
following PCR parameters: 95°C for 2 minutes, then 40 cycles of 95°C for 5 seconds, 60°C for 15
seconds, and 70°C for 34 seconds. Each microRNA target was amplified in duplicate technical
replicates for each sample with negative amplification on each plate.
Data Analysis
Data analysis was performed using QuantStudio™ Real-Time PCR software v1.3 (Life
Technologies). The Cq threshold baseline was set to 0.010. The averaged replicate Cq scores for
each miRNA candidate in a body fluid sample were subtracted from the averaged C q score for let7g and let-7i from the same sample to determine the Δ Cq, or relative expression of the miRNA (Δ
Cq = Cq (target) − Cq (avg let-7g & let-7i)). A wilcoxon rank sum test for significance was performed for
populations under 50 samples and an equal variance t-test was performed for populations of 50
samples. A Quadratic Discriminant Analysis (RQDA) (30) classification model was used to
determine its ability to correctly predict the body fluid. To evaluate each method, a 10-fold cross
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validation procedure was used to ensure that each observation was in a validation set. The quadratic
discriminant analysis model incorporates an “Other” category in order to allow for prediction of
unknown samples outside of the commonly seen forensic science samples of blood, menstrual
blood, feces, urine, saliva, and semen. All samples that come into a forensic science laboratory
may not be a human body fluid; they may be an organ tissue, another species’ body fluid, or simply
not a biological sample at all. A total of 500 simulated data points comprised of the other category
and formed a cloud around our dataset.
The analysis was performed in R v3.4.2 (R Foundation for Statistical Computing, Vienna,
Austria). Confusion matrices were generated and the percentage of samples that classified
correctly was calculated. The data for those that were misclassified were examined closely to
determine any patterns associated with the misclassification.
Results and Discussion
The first objective of this project was to evaluate potential targets for menstrual blood.
miR-141 and miR-412 were identified from the literature. The miRNA candidates for menstrual
blood miR-141, miR-412 and reference miRNAs let-7g and let-7i were evaluated in a stepwise
approach designed to evaluate the candidates while also economizing on reagents and funding.
The initial step started with five samples each of blood, saliva, vaginal fluid, semen, and feces,
urine, and ten samples of menstrual blood from different donors. Figure 1 and Figure 2 show the
relative expression of miRNA candidates miR-141 and miR-412, respectively. Due to the small
sample size, a Wilcoxon Rank Sum Exact Test was performed in order to determine if differences
noted between blood and menstrual blood and menstrual blood and vaginal fluid were real. For
miR-141 the p-value was 0.002797 (p-value <0.05) which indicated there was a significant
difference between blood and menstrual blood. For miR-412 the p-value was 0.7972 (p-value
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>0.05), indicating that there was not a significant difference between blood and menstrual blood;
however, the p-value of 0.03357 (p-value <0.05) indicated a significant difference between
menstrual blood and vaginal fluid. Since menstrual blood has had difficulties classifying as vaginal
fluid (Table1), miR-412 was evaluated further to help differentiate between menstrual blood and
vaginal fluid. Analysis of 15 additional samples for blood, saliva, vaginal fluid, semen, and urine,
and ten samples in menstrual blood for a total of 20 samples for every body fluid from different
donors was performed in order to evaluate the expression levels in a larger population sampling.
For miR-141, the p-value was 5.944E-05 (p-value <0.05), indicating that there continued to be
significant difference of expression between blood and menstrual blood. For miR-412 the p-value
was 0.06742 (p-value >0.05) indicated there was not a significant difference between blood and
menstrual blood but the p-value of 0.0001322 (p-value <0.05) indicated continuing significant
difference between menstrual blood and vaginal fluid. Figure 3 and Figure 4 show the relative
expressions of miRNA candidates miR-141 and miR-412 respectively after the population
expansion. After the population increase to 20 samples, both miR-141 and miR-412 continued to
show potential for being able to distinguish between peripheral blood and menstrual blood and
even menstrual blood and vaginal, due to their consistently decreasing p-values. Thus, both miRs
were selected to be evaluated in the full population study alongside the reduced miRNA panel.
Fifty samples of feces, semen, saliva, vaginal, 49 samples of blood, and 46 samples of urine were
tested with miR-141 and miR-412. Figure 5 and Figure 6 show the relative expressions of miRNA
candidates miR-141 and miR-412 respectively. Due to the large sample size, an equal variance ttest was performed to determine if there was significant difference between menstrual blood and
peripheral blood and menstrual blood and vaginal fluid. For miR-141, the p-value was 2.2E-16 (pvalue <0.05), indicating that there was significant difference of expression between blood and
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menstrual blood. Again, as the population size continues to increase, the p-value has consistently
decreased indicating a greater chance of being able to differentiate between menstrual blood and
peripheral blood using miR-141. For miR-412 the p-value was 7.232E-12 (p-value <0.05)
indicated there was a significant difference between blood and menstrual blood. As with miR-141,
miR-412 now showed the possibility to be able differentiate between menstrual blood and
peripheral blood as it followed the same trend of consistently decreasing as the population size
increased. The p-value between menstrual blood and vaginal fluid was of 0.001474 (p-value
<0.05) which indicated a significant difference between menstrual blood and vaginal fluid.
Although the p-value was still less than 0.05, unlike the previous data of miR-141 and miR-412,
the p-value between menstrual blood and vaginal fluid increased. The difference between the
means of menstrual blood and vaginal fluid was greater in the 20 sample population than the 50
sample population, which explains why the p-value increased with the population increase. With
the collection of more sample data, miR-412 may not prove to be the most ideal marker for
differentiating between menstrual blood and vaginal fluid.
The second objective of this project was to improve the reduced miRNA panel
validated in the Seashols-Williams Laboratory by increasing the ability of this panel to accurately
predict menstrual blood. As noted earlier, previous work had demonstrated the Seashols-Williams
panel capable of accurately categorizing menstrual blood in 62% of samples analysed with overall
body fluid prediction accuracies at 88% using quadratic discriminant analysis. Using the
previously validated panel, out of the 50 samples of menstrual blood tested, 19 samples were
misclassified. (Table 1) After the addition of miR-141 to the panel, the overall prediction accuracy
increased to 89.7% (Table 2). While the menstrual blood prediction accuracy decreased to 58%,
there was an increase in all other body fluids prediction accuracy except for semen which remained
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the same. When miR-412 was added to the previously validated panel without miR-141, a
prediction accuracy lower than the starting prediction accuracy was observed (data not shown).
miR-412 was then added to panel along with miR-141 and resulted in an overall prediction
accuracy of 91.36% (Table 3). There was an increase in prediction accuracy in every body fluid
except for blood and vaginal fluid which remained the same. Menstrual blood had a prediction
accuracy of 68%, an increase in 6% from the starting accuracy. Menstrual blood often
misclassifying as vaginal is not unexpected since menstrual blood samples are a mixture of
menstrual blood and vaginal fluid. The assay is primarily detecting the vaginal fluid rather than
the menstrual blood. The addition of miR-141 and miR-412 increased the overall predication
accuracy by 3.36% (Table 4), indicating that including miR-141 and miR-412 to the panel would
be beneficial.

Conclusion
In this study, candidate miRNAs miR-141 and miR-412 were analyzed for their ability to
differentiate between menstrual blood and peripheral blood. Our data suggest that using both miR141 and miR-412 together has a greater advantage instead of only incorporating one into the panel.
While the addition of miR-141 and miR-412 increased prediction accuracy to 91.36%, menstrual
blood is still being classified as vaginal fluid 30% of the time. The problem with menstrual blood
classifying as vaginal fluid is a sample mixture issue. Future work with miRNAs as body fluid
identifiers will need determine the ability of this panel of miRNAs to distinguish body fluid
mixtures. Incorporation of the other category can help with misclassifications by allowing
prediction outside of our limits such as a body fluid mixture. Mixture analysis will be challenging
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due to the cross reactivity and differential expression patterns of miRNAs but, understanding the
degree of correlation between markers can help with the deconvolution of mixture samples (Figure
7).
The use of miRNA body fluid identification assays has the potential to be developed into
a multiplex that could be easily integrated into forensic science laboratories, along with a web
based interface to predict an unknown body fluid. While using miRNAs can help overcome the
limitations of current body fluid identification methods, further research is still needed before it
can be implemented into forensic science laboratories.
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Table 1. Confusion matrix dataset of previously validated miRNA panel for body fluid
identification.

A Quadratic Discriminant Analysis with 10-fold cross validation and markers miR-200b, miR-320c, miR-10b, and miR-891a in
DNA extracts. An overall 88% classification was obtained.
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Figure 1. Differential Expression Patterns of miR-141. Box plots of the Δ Cq values of miR141 in each body fluid. (n=5 samples for blood, feces, saliva, semen, urine and vaginal fluid,
average of duplicate technical replicate wells. n=10 samples in menstrual blood, average of
duplicate technical replicate wells). *Indicates statistically significant difference, p-value <0.05.
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Figure 2. Differential Expression Patterns of miR-412. Box plots of the Δ Cq values of miR412 in each body fluid. (n=5 samples for blood, feces, saliva, semen, urine and vaginal fluid,
average of duplicate technical replicate wells. n=10 samples in menstrual blood, average of
duplicate technical replicate wells). *Indicates statistically significant difference, p-value <0.05.
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Figure 3. Differential Expression Patterns of miR-141. Box plots of the Δ Cq values of miR141 in each body fluid. (n=20 samples, average of duplicate technical replicate wells). *Indicates
statistically significant difference, p-value <0.05.
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Figure 4. Differential Expression Patterns of miR-412. Box plots of the Δ Cq values of miR412 in each body fluid. (n=20 samples, average of duplicate technical replicate wells). *Indicates
statistically significant difference, p-value <0.05.
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Figure 5. Differential Expression Patterns miR-141. Box plots of the Δ Cq values of miR-141
in each body fluid. (n=50 for feces, menstrual blood, saliva, semen, vaginal fluid. n=49 for
blood. n=46 for urine.)
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Figure 6. Differential Expression Patterns of miR-412. Box plots of the Δ Cq values of miR412 in each body fluid. (n=50 for feces, menstrual blood, saliva, semen, vaginal fluid. n=49 for
blood. n=46 for urine.)
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Table 2. Confusion matrix dataset using the previously validated miRNA panel and miR-141.

A Quadratic Discriminant Analysis with 10-fold cross validation using markers miR-200b, miR-320c, miR-10b, miR-891a, and
miR-141 in DNA extracts. An 89.7% classification was obtained.
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Table 3. Confusion matrix dataset using the previously validated panel and miR-141 and miR412.

A Quadratic Discriminant Analysis with 10-fold cross validation using markers miR-200b, miR-320c, miR-10b, miR-891a, miR141, and miR-412 in DNA extracts. A 91.36% classification was obtained.
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Table 4. Comparison table of the overall correct classification of each body fluid using the
previously validated panel and miR-141 and miR-412.
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Figure 7. Pairwise scatter plot of relative expression of microRNA’s: miR-200b, miR-320c,
miR-10b, miR-891a, miR-141, and miR-412.
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